ReviewDrugs in R&D2018
The Risk of Thrombocytopenia During Valproic Acid Therapy: A Critical Summary of Available Clinical Data.
Review in Drugs in R&D, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Trial
- Contralateral pulmonary resection with drug-induced thrombocytopenia after previous lobectomy in chest trauma: a case report.Journal of trauma and injury · 2026Article
- Sodium valproate: balancing benefits and risks especially in people of childbearing potential.Australian prescriber · 2026Review
- Psychopharmacological Treatment in Patients with Heart Failure: A Narrative Review of Mood Stabilizers and Antipsychotics.Brain sciences · 2026Review
- Acute Vaginal Bleeding as the Initial Manifestation of Multifactorial Thrombocytopenia: A Case Report.Cureus · 2026Article
- Myelodysplasia From Valproic Acid Resolved by Cessation.Case reports in hematology · 2026Article
- Valproate Induced Thrombocytopenia and Pseudo-Pelger-Huët Anomaly: A Diagnostic Clue from Peripheral Smear.Indian journal of pediatrics · 2025Article
- Review
- Risk factors for thrombocytopenia associated with intravenous valproic acid therapy in pediatric patients undergoing neurosurgical operations.Scientific reports · 2025Article
- Nomogram for the prediction of valproic acid induced platelet decline: a nested case-control study.Scientific reports · 2025Article
- Investigating the Relationship Between Anti-seizure Medications and Bleeding Disorders: A Comprehensive Review of the Current Literature.Drugs - real world outcomes · 2025Review
- Levetiracetam and valproic acid in glioma: antiseizure and potential antineoplastic effects.Future oncology (London, England) · 2025Review
- Pharmacological strategies for preventing post-stroke seizures and epilepsy.Frontiers in neurology · 2025Review
- Cilostazol geno-protective effects mitigate carbamazepine-induced genotoxicity in human cultured blood lymphocytes.Toxicology reports · 2024Article
- The Many Faces of Immune Thrombocytopenia: Mechanisms, Therapies, and Clinical Challenges in Oncological Patients.Journal of clinical medicine · 2024Review
- A Biobehavioral Perspective on Caring for Allogeneic Hematopoietic Stem Cell Transplant Survivors with Graft-Versus-Host Disease.Transplantation and cellular therapy · 2024Article
- Valproate-Induced Thrombocytopenia: A Case Report.Cureus · 2024Article
- Valproic Acid-Induced Thrombocytopenia in Treatment-Resistant GABRB3 Genetic Epilepsy: A Case Report.Cureus · 2024Article
- The impact of epilepsy and antiseizure medications on pregnancy and neonatal outcomes: A nationwide cohort study.Brain and behavior · 2023Article
- A Retrospective Case Series on Valproic Acid for Early Post-Traumatic Seizure Prophylaxis After Traumatic Brain Injury in Patients With Concomitant Agitation.Hospital pharmacy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Valproate is an effective anti-epileptic and mood stabilizer drug, but its prescription may be complicated by the development of thrombocytopenia. The purpose of the present manuscript is to provide a critical overview about the risk of thrombocytopenia during treatment with valproate. A search of the main database sources has been conducted to identify relevant papers about the topic. In the studies with a larger sample size (> 150 subjects), thrombocytopenia occurred in 12-18% of subjects receiving treatment with valproate. Advanced age, female gender, and high doses were found to be risk factors for the development of thrombocytopenia during treatment with valproate. Future research is needed to clarify the clinical impact of the occurrence of thrombocytopenia during valproate treatment (e.g., the risk of life-threatening events such as stroke or the development of thrombocytopenia during short- versus long-term administration, or oral versus intravenous formulations).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.